Glasdegib
Daurismo (glasdegib) is a small molecule pharmaceutical. Glasdegib was first approved as Daurismo on 2018-11-21. It is used to treat myeloid leukemia acute in the USA. It has been approved in Europe to treat myeloid leukemia acute. The pharmaceutical is active against smoothened homolog. Daurismo's patent is valid until 2036-04-13 (FDA).
| Trade Name | Daurismo |
|---|---|
| Common Name | Glasdegib |
| Indication | myeloid leukemia acute |
| Drug Class | Hedgehog signaling inhibitors |
